Merck & Co., Inc. (MRK) Competitors

$111.26 -0.12 (-0.11%)

As of 03:51 PM Eastern

MRK vs. AMGN, GILD, MRNA, VRTX, and ABBV

Should you be buying Merck & Co., Inc. stock or one of its competitors? The main competitors of Merck & Co., Inc. include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Merck & Co., Inc. compare to Amgen?

Merck & Co., Inc. (NYSE:MRK) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Merck & Co., Inc. has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Amgen has a net margin of 20.96% compared to Merck & Co., Inc.'s net margin of 13.59%. Amgen's return on equity of 137.41% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
Amgen	20.96%	137.41%	13.28%

Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 3.1%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. Merck & Co., Inc. pays out 95.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 70.1% of its earnings in the form of a dividend. Merck & Co., Inc. has raised its dividend for 14 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Merck & Co., Inc. had 11 more articles in the media than Amgen. MarketBeat recorded 54 mentions for Merck & Co., Inc. and 43 mentions for Amgen. Merck & Co., Inc.'s average media sentiment score of 1.13 beat Amgen's score of 0.89 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	39 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Amgen	27 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Merck & Co., Inc. has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.77B	4.18	$18.25B	$3.55	31.34
Amgen	$37.22B	4.77	$7.71B	$14.37	22.89

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Merck & Co., Inc. presently has a consensus target price of $128.18, suggesting a potential upside of 15.20%. Amgen has a consensus target price of $357.12, suggesting a potential upside of 8.55%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts plainly believe Merck & Co., Inc. is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

Summary

Amgen beats Merck & Co., Inc. on 12 of the 19 factors compared between the two stocks.

How does Merck & Co., Inc. compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Gilead Sciences presently has a consensus target price of $157.04, indicating a potential upside of 17.50%. Merck & Co., Inc. has a consensus target price of $128.18, indicating a potential upside of 15.20%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 3.1%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 95.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and Merck & Co., Inc. has raised its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Gilead Sciences has a net margin of 30.99% compared to Merck & Co., Inc.'s net margin of 13.59%. Gilead Sciences' return on equity of 48.19% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Merck & Co., Inc.	13.59%	27.55%	10.73%

In the previous week, Gilead Sciences had 18 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 72 mentions for Gilead Sciences and 54 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 1.13 beat Gilead Sciences' score of 0.68 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	31 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Positive
Merck & Co., Inc.	39 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Merck & Co., Inc. has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.74B	5.58	$8.51B	$7.34	18.21
Merck & Co., Inc.	$65.77B	4.18	$18.25B	$3.55	31.34

Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500.

Summary

Gilead Sciences beats Merck & Co., Inc. on 13 of the 20 factors compared between the two stocks.

How does Merck & Co., Inc. compare to Moderna?

Merck & Co., Inc. (NYSE:MRK) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Merck & Co., Inc. currently has a consensus target price of $128.18, indicating a potential upside of 15.20%. Moderna has a consensus target price of $35.73, indicating a potential downside of 31.72%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities research analysts clearly believe Merck & Co., Inc. is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Merck & Co., Inc. has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Merck & Co., Inc. has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.77B	4.18	$18.25B	$3.55	31.34
Moderna	$2.20B	9.42	-$2.82B	-$8.15	N/A

Merck & Co., Inc. has a net margin of 13.59% compared to Moderna's net margin of -143.55%. Merck & Co., Inc.'s return on equity of 27.55% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
Moderna	-143.55%	-26.64%	-19.32%

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Merck & Co., Inc. had 10 more articles in the media than Moderna. MarketBeat recorded 54 mentions for Merck & Co., Inc. and 44 mentions for Moderna. Merck & Co., Inc.'s average media sentiment score of 1.13 beat Moderna's score of 0.52 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	39 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Moderna	20 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Merck & Co., Inc. beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Merck & Co., Inc. compare to Vertex Pharmaceuticals?

Merck & Co., Inc. (NYSE:MRK) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Merck & Co., Inc. has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Merck & Co., Inc. currently has a consensus target price of $128.18, indicating a potential upside of 15.20%. Vertex Pharmaceuticals has a consensus target price of $555.17, indicating a potential upside of 27.50%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85

Merck & Co., Inc. has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.77B	4.18	$18.25B	$3.55	31.34
Vertex Pharmaceuticals	$12.00B	9.21	$3.95B	$16.86	25.83

Vertex Pharmaceuticals has a net margin of 35.51% compared to Merck & Co., Inc.'s net margin of 13.59%. Merck & Co., Inc.'s return on equity of 27.55% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

In the previous week, Vertex Pharmaceuticals had 3 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 57 mentions for Vertex Pharmaceuticals and 54 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 1.13 beat Vertex Pharmaceuticals' score of 0.88 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	39 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	30 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Merck & Co., Inc. on 11 of the 16 factors compared between the two stocks.

How does Merck & Co., Inc. compare to AbbVie?

Merck & Co., Inc. (NYSE:MRK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Merck & Co., Inc. has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 3.1%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Merck & Co., Inc. pays out 95.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Merck & Co., Inc. currently has a consensus target price of $128.18, indicating a potential upside of 15.20%. AbbVie has a consensus target price of $252.90, indicating a potential upside of 24.78%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Merck & Co., Inc. has higher revenue and earnings than AbbVie. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.77B	4.18	$18.25B	$3.55	31.34
AbbVie	$62.82B	5.70	$4.23B	$2.03	99.84

Merck & Co., Inc. has a net margin of 13.59% compared to AbbVie's net margin of 5.79%. Merck & Co., Inc.'s return on equity of 27.55% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
AbbVie	5.79%	-911.57%	13.43%

In the previous week, AbbVie had 7 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 61 mentions for AbbVie and 54 mentions for Merck & Co., Inc.. AbbVie's average media sentiment score of 1.16 beat Merck & Co., Inc.'s score of 1.13 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	39 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

AbbVie beats Merck & Co., Inc. on 12 of the 20 factors compared between the two stocks.

Get Merck & Co., Inc. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRK vs. The Competition

Export

Metric	Merck & Co., Inc.	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$274.54B	$289.54B	$6.18B	$22.92B
Dividend Yield	3.03%	2.83%	2.78%	4.02%
P/E Ratio	31.31	25.83	20.71	29.03
Price / Sales	4.18	4.77	527.52	24.74
Price / Cash	9.75	12.33	27.81	19.21
Price / Book	5.24	7.29	9.80	4.66
Net Income	$18.25B	$11.61B	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.09%
1 Month Performance	-8.36%	-1.88%	6.48%	4.17%
1 Year Performance	46.63%	22.84%	42.26%	29.27%

Merck & Co., Inc. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRK Merck & Co., Inc.	4.7674 of 5 stars	$111.26 -0.1%	$128.18 +15.2%	+46.6%	$274.54B	$65.77B	31.31	75,000	Positive News Analyst Revision
AMGN Amgen	4.3839 of 5 stars	$324.71 -1.6%	$357.12 +10.0%	+24.8%	$175.27B	$36.75B	22.60	31,500	Analyst Revision
GILD Gilead Sciences	4.6754 of 5 stars	$132.55 +0.7%	$157.35 +18.7%	+35.6%	$164.69B	$29.44B	19.60	17,000	Earnings Report Dividend Announcement Analyst Forecast
MRNA Moderna	1.341 of 5 stars	$47.34 +4.4%	$34.60 -26.9%	+124.1%	$18.69B	$1.94B	N/A	4,700	Gap Up
VRTX Vertex Pharmaceuticals	4.3713 of 5 stars	$428.04 +1.0%	$554.83 +29.6%	+1.1%	$108.90B	$12.00B	27.93	6,400	Earnings Report Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MRK) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Merck & Co., Inc. (MRK) Competitors

MRK vs. AMGN, GILD, MRNA, VRTX, and ABBV

How does Merck & Co., Inc. compare to Amgen?

Summary

How does Merck & Co., Inc. compare to Gilead Sciences?

Summary

How does Merck & Co., Inc. compare to Moderna?

Summary

How does Merck & Co., Inc. compare to Vertex Pharmaceuticals?

Summary

How does Merck & Co., Inc. compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRK vs. The Competition

Merck & Co., Inc. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Merck & Co., Inc. (MRK) Competitors

MRK vs. AMGN, GILD, MRNA, VRTX, and ABBV

How does Merck & Co., Inc. compare to Amgen?

Which has more risk & volatility, MRK or AMGN?

Is MRK or AMGN more profitable?

Is MRK or AMGN a better dividend stock?

Does the media favor MRK or AMGN?

Which has better earnings and valuation, MRK or AMGN?

Do insiders and institutionals hold more shares of MRK or AMGN?

Do analysts prefer MRK or AMGN?

Summary

How does Merck & Co., Inc. compare to Gilead Sciences?

Do analysts rate GILD or MRK?

Is GILD or MRK a better dividend stock?

Do insiders and institutionals have more ownership in GILD or MRK?

Is GILD or MRK more profitable?

Does the media favor GILD or MRK?

Which has better earnings and valuation, GILD or MRK?

Which has more risk and volatility, GILD or MRK?

Summary

How does Merck & Co., Inc. compare to Moderna?

Do analysts prefer MRK or MRNA?

Which has more risk & volatility, MRK or MRNA?

Which has higher valuation and earnings, MRK or MRNA?

Is MRK or MRNA more profitable?

Do institutionals and insiders believe in MRK or MRNA?

Does the media favor MRK or MRNA?

Summary

How does Merck & Co., Inc. compare to Vertex Pharmaceuticals?

Which has more risk & volatility, MRK or VRTX?

Do analysts prefer MRK or VRTX?

Which has higher valuation and earnings, MRK or VRTX?

Is MRK or VRTX more profitable?

Does the media favor MRK or VRTX?

Do institutionals and insiders believe in MRK or VRTX?

Summary

How does Merck & Co., Inc. compare to AbbVie?

Which has more risk and volatility, MRK or ABBV?

Is MRK or ABBV a better dividend stock?

Do analysts prefer MRK or ABBV?

Which has preferable earnings & valuation, MRK or ABBV?

Is MRK or ABBV more profitable?

Does the media favor MRK or ABBV?

Do insiders and institutionals have more ownership in MRK or ABBV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRK vs. The Competition

Merck & Co., Inc. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools